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Myoglobin, encoded by MB, is a small cytoplasmic globular hemoprotein highly expressed
in cardiac myocytes and oxidative skeletal myoﬁbers. Myoglobin binds O2, facilitates its
intracellular transport and serves as a controller of nitric oxide and reactive oxygen species.
Here, we identify a recurrent c.292C>T (p.His98Tyr) substitution inMB in fourteen members
of six European families suffering from an autosomal dominant progressive myopathy with
highly characteristic sarcoplasmic inclusions in skeletal and cardiac muscle. Myoglobinopathy
manifests in adulthood with proximal and axial weakness that progresses to involve distal
muscles and causes respiratory and cardiac failure. Biochemical characterization reveals
that the mutant myoglobin has altered O2 binding, exhibits a faster heme dissociation rate
and has a lower reduction potential compared to wild-type myoglobin. Preliminary studies
show that mutant myoglobin may result in elevated superoxide levels at the cellular level.
These data deﬁne a recognizable muscle disease associated with MB mutation.
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Myoglobin, the pigment that gives muscle its red color,is a small cytoplasmic globular hemoprotein highlyexpressed in cardiac and oxidative skeletal
muscle ﬁbers1.
By reversibly binding O2, myoglobin buffers intracellular O2
concentrations, facilitates intracellular O2 transport and serves as
a reservoir of oxygen during hypoxic and anoxic conditions1–3. In
addition, myoglobin is implicated in vivo in the control of redox
pathways in skeletal and cardiac myocytes, acting as scavenger of
reactive oxygen species (ROS) and nitric oxide4,5.
Myoglobin was the ﬁrst protein for which a three-dimensional
structure was determined by X-ray crystallography6. The back-
bone of myoglobin consists of eight α-helices, assigned the
letters A to H, that wrap around a central pocket containing
a heme group, a porphyrin ring that contains a central bound
iron atom that is normally in the ferrous oxidation state.
Its heme active site is responsible for reversible binding to
various ligands including oxygen, carbon monoxide and nitric
oxide7.
Myoglobin is encoded by the myoglobin gene (MB) on human
chromosome 22q12.37.
Here we describe myoglobinopathy, a disease caused by a
recurrent MB mutation found in 14 patients from six unrelated
European families suffering from an autosomal dominant myo-
pathy with variable cardiac involvement and characteristic sar-
coplasmic inclusions in skeletal and cardiac muscle. We show that
mutation of MB alters the kinetics and thermodynamics of O2
binding and may result in elevated superoxide levels.
Results
The clinical phenotype of myoglobinopathy. We studied 14
patients from six unrelated European families (F1–F6), (Fig. 1),
suffering from an autosomal dominant myopathy with variable
cardiac involvement, identiﬁed by their highly characteristic
features on muscle biopsies. The clinical presentation was
homogeneous among all patients and is summarized in Table 1.
Age of onset ranged between 33 and 49 years. Initial symptoms
were proximal lower limb, pelvic girdle, and axial muscle weak-
ness, manifesting with difﬁculties climbing stairs, rising from
squatting and standing up from the lying position. Two patients
had, in addition, weakness and atrophy of thenar muscles from
disease onset. Over the following years, the disease slowly pro-
gressed to involve distal leg and hand muscles, proximal muscles
of upper limbs, and neck muscles. Five patients complained of
dysphagia. Facial and extraocular muscles were not involved.
Progression was slow; most patients developed respiratory failure
requiring nocturnal non-invasive ventilatory support 10 years
after disease onset and they became wheelchair dependent 15–20
years after disease onset. Cardiac involvement, revealed by
ultrasound, magnetic resonance imaging (MRI) or post mortem
myocardium examination, was observed in six individuals. Car-
diac MRI in patient F2, II:2 showed a dilated cardiomyopathy
with extensive and diffuse areas of late gadolinium enhancement,
indicative of ﬁbrosis at the epicardium and mesocardium, but no
involvement of the endocardium, (Supplementary Fig. 1). Six
patients died between 18 and 30 years after disease onset, from
respiratory and/or cardiac failure.
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Fig. 1 Pedigrees from the six families affected with myoglobinopathy. F1 and F2 Spanish, F3: Swedish, F4 and F5: French, F6: Dutch. Squares represent
males; circles, females; ﬁlled black symbols indicate affected individuals; ﬁlled gray symbol, clinically affected, but not molecularly tested individuals; and
slash, deceased
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Serum CK levels were normal to mildly increased, except for
a single individual who showed CK levels up to sevenfold above
the upper normal limit. EMG was consistent with a myopathy
with spontaneous activity at rest. Nerve conduction studies
were normal. Muscle imaging studies showed a consistent pattern
characterized by fatty degenerative changes in paraspinal and
gluteal muscles, especially gluteus maximus and medius. At mid-
thigh, there was preferential involvement of the adductor magnus,
semimembranosus, long head of biceps femoris and vastus
intermedius, except in individual F6, II:4 who showed predomi-
nant involvement of the anterior compartment. At the mid-leg,
the soleus was always the ﬁrst and most affected muscle (Fig. 2).
Muscle pathology features associated with MB mutation.
Muscle biopsies showed characteristic sarcoplasmic bodies in
both Type 1 and Type 2 myoﬁbers in all studied patients,
including pre-symptomatic individuals, irrespective of the site of
the biopsy (Fig. 3 and Supplementary Table 1). The sarcoplasmic
bodies were rounded or oval, appeared brown on hematoxylin
and eosin and red on the modiﬁed Gomori’s trichrome stain.
They had a glassy appearance and were easily visualized with all
stains and even in non-stained sections.
They exhibited autoﬂuorescence emission in a wide range of
visible laser excitation lines (Supplementary Fig. 2). Besides the
sarcoplasmic bodies, the majority of muscle biopsies showed non-
speciﬁc myopathic changes with increased myoﬁber size variation,
increased numbers of internal nuclei and type 1 ﬁber predomi-
nance (Supplementary Table 1). Most muscle biopsies, particularly
those showing advanced pathological lesions, showed cytoplasmic
vacuoles ﬁlled with granular basophilic material, displaying strong
acid phosphatase activity and lysosome-associated membrane
protein 1 (LAMP1) immunoreactivity (Fig. 3), indicating that they
contained lysosomes. No major architectural changes were
observed on NADH, SDH, and COX reactions apart from the
lack of oxidative activity at the site of vacuoles. Myoglobin, p62,
and ubiquitin immunoreactivity was observed in abnormal
myoﬁber regions containing vacuoles and in some but not all
sarcoplasmic bodies (Fig. 4), demonstrating abnormal protein
aggregation (Fig. 4). However, myoglobin immunostaining was
not particularly useful for the diagnosis. Under electron micro-
scopy, the inclusions appeared as very dense bodies measuring
0.3–2.5 µm, often located next to myonuclei or dispersed between
myoﬁbrils (Fig. 5a–d and Fig. 5e–g). Some were membrane bound,
whereas others were not. Some were denser than others, likely
reﬂecting different stages of the pathological process. Autophagic
vacuoles with cellular debris, myelin ﬁgures, and ﬁlaments
measuring 8–12 nm were additional ﬁndings. Sarcoplasmic bodies
were present in respiratory and cardiac muscles obtained post
mortem from individual F1, II:7 and in cardiac muscle from
Table 1 Phenotypic features of myoglobinopathy
Family 1 Family 2 Family 3 Family 4 Family 5 Family 6
Inheritance pattern AD AD AD AD unknown unknown
Myoglobin mutation His98Tyr His98Tyr His98Tyr His98Tyr His98Tyr His98Tyr
Country of origin Spain Spain Sweden France France Netherlands
No. of patients 2 1 6 3 1 1
Mean age of onset
(range)
37.5 (36–39) 38 44.5 (39–49) 46 (44–48) 40 33
Gender (female/male) 0/2 1/0 2/4 2/1 0/1 0/1
Initial symptoms Proximal LL and
axial weakness
(2/2)
Proximal LL and
axial weakness
(1/1)
Distal hand weakness
(2/6)
Proximal LL and axial
weakness (6/6)
Proximal LL and axial
weakness (3/3)
Proximal LL
weakness (1/1)
Proximal LL and
axial weakness
(1/1)
Symptoms at advanced disease
Distribution of
weakness
Proximal and
axial > distal 4
EE
Proximal and
axial > distal 4
EE
Proximal and axial >
distal 4 EE
Proximal and distal 4
EE > axial
Proximal and
axial > distal 4
EE
Proximal and
axial > distal legs
Involvement of hand
muscles
2/2 1/1 6/6 2/2** 1/1 0/1
Facial weakness 0/2 0/1 0/6 0/2 0/1 0/1
Muscle atrophy 2/2 1/1 6/6 2/2 0/1 1/1
Dysphagia 2/2 0/1 2/4 0/2 1/1 0/1
Respiratory
insufﬁciency
2/2 1/1 2/6 1/2 1/1 1/1
Cardiac involvement* 2/2 1/1 2/6 0/2 1/1 0/1
Clinical outcome
Mean age at wheelchair
dependency
54 65 56 (4/6 patients
wheelchair
dependent, 2/6
ambulant)
66 (1/3 patients
wheelchair
dependent, 2/3
ambulant)
56 47
Mean age at death
(range)
60.5 (54–67) – 64 (58–71) 72 – –
Laboratory studies
CK fold elevation above
normal levels
1.5–2 2 1.5–4 2.3–3.7 4 3.5–7
EMG Myogenic with
spontaneous
activity at rest
Myogenic with
spontaneous
activity at rest
Myogenic with
spontaneous activity
at rest
Myogenic with
spontaneous activity
at rest
Myogenic with
spontaneous
activity at rest
Myogenic with
spontaneous
activity at rest
*As revealed by cardiac ultrasound, cardiac MRI, or by post mortem examination of cardiac muscle. ** Individual III:2 from Fam 4 is in the early stages of the disease and therefore not included in
symptoms at advanced disease items. EE: extremities; LL: lower limbs
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individual F3, III:5 (Fig. 5d and Supplementary Fig. 3), thus
indicating that cardiomyopathy was a primary consequence of the
disease and not secondary to respiratory failure.
Identiﬁcation of p.His98Tyr MB substitution in six families.
To identify the molecular cause of this myopathy two
independent groups used two different strategies. The Australian
group used whole-exome sequencing of three affected individuals
from two Spanish families (F1, II:5 and II:7 and F2, II:2), and
gene prioritization of shared variants using skeletal muscle
expression enrichment data from FANTOM58. This identiﬁed the
same heterozygous missense variant (c.292C>T, p.His98Tyr) in
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Fig. 2 Muscle imaging in myoglobinopathy. Muscle CT scan from individuals F1, II: 7 (a–c); F4, II: 4 (d–f); and F5, II: 6 (g–i) at the pelvic (a, d and g), mid-
thigh (b, e, and h), and mid-leg (c, f, and i). At the pelvis, there is involvement of the gluteus maximus, medius, and minimus. At mid-thigh, there is
preferential involvement of the posterior compartment, specially, of the adductor magnus, biceps femoris, and semimembranosus. At the mid-leg, the
soleus is the ﬁrst and most-affected muscle
Fig. 3 Histochemical features of myoglobinopathy. a Anterior tibialis muscle biopsy from individual F3, III: 15, 10 years prior to the onset of symptoms,
stained with hematoxylin and eosin, showing several rounded brown inclusions (arrows) (sarcoplasmic bodies) in the majority of myoﬁbers and very small
vacuoles in some myoﬁbers (arrowhead in a). b, c Biceps brachii from individual F1, II: 7, 15 years after disease onset. b Note the presence of collections of
sarcoplasmic bodies within the rimmed vacuoles. d, e Sarcoplasmic bodies appear red on modiﬁed Gomori trichrome stain. e In muscle biopsies with more
advanced pathological lesions, large numbers of rimmed vacuoles are observed. f No major architectural changes are seen on NADH reaction, apart
from lack of oxidative activity at the site of vacuoles. g Fast myosin immunohistochemistry demonstrate the presence of sarcoplasmic bodies in both type 1
(slow) and 2 (fast) myoﬁbers. hMyoﬁber regions containing vacuoles display strong phosphatase activity, and LAMP1 i immunoreactivity. Scale bar in a, e,
f, g, and h= 50 µm; scale bar in b, c, d, and i= 20 µm
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the myoglobin gene (MB) in all three affected individuals. The
Swedish group, studying family F3, identiﬁed one region on
chromosome 22 through genome-wide linkage analysis, with a
statistically signiﬁcant LOD score. Reﬁnement of the peak with
further markers and clariﬁcation of the disease state in family
members, resulted in a maximum multipoint LOD score of 5.8 at
D22S685 (Supplementary Fig. 4). Targeted capture and sequen-
cing of genes within the linkage region in eight individuals, six
affected and two unaffected, revealed in all the affected family
members, the presence of the same MB (c.292C>T, p.His98Tyr)
variant. Sanger sequencing conﬁrmed segregation of the variant
with the disease in all available family members and in three
additional families (F4, F5, and F6). The variant involves a highly
conserved residue in the proximity of the oxygen-binding
heme group (Supplementary Fig. 5), it is absent in all unaf-
fected relatives tested, is not present in the 1000genomes, ExAC
(http://exac.broadinstitute.org/) or gnomAD ((http://gnomad.
broadinstitute.org) data sets and was present on different hap-
lotypes. Moreover, all in silico predictors suggested the observed
substitution in MB is deleterious: MutationAssessor (medium
functional impact, FI score 3.175), MutationTaster (disease-
causing, p=0.999), PolyPhen-2 (probably damaging, score 1.000),
Provean (deleterious, score −4.093) and SIFT (damaging, score
0.001). Thus, we have compelling evidence across six families that
the same MB (c.292C>T, p.His98Tyr) variant is responsible for
the observed myopathy.
Haplotype analysis using microsatellites within 3Mbp of the
MB gene indicated at least three different haplotypes within the
six families, suggesting that the c.292C>T variant is a recurrent
variant originating on different ancestral backgrounds (Supple-
mentary Table 2). Furthermore, the analysis of haplotypes in
family F5 showed that the affected and two unaffected siblings
had identical alleles, suggesting that in the affected individual the
variant probably arose de novo (Supplementary Table 2). No
samples from the parents in family F5 were available for
conﬁrmation.
Myoglobin knockout mice have a binary phenotype. Two-
thirds die in utero at ~ E9.5-E10.59, but those that survive live
to adulthood with little sign of functional effects, because of
multiple compensatory mechanisms10. We therefore hypothe-
sized a dominant gain of function as the cause of the disease
in the families and used multiple methods to investigate the
pathomechanism.
NanoSIMS analysis of the sarcoplasmic bodies. Correlative
electron microscopy and NanoSIMS (Nanoscale Secondary Ion
Mass Spectrometry) analysis revealed high sulfur content and
small iron Fe signals in the sarcoplasmic bodies (Fig. 5h–j). Of
note, sulfur is a component of antioxidant systems of cells and
reactive sulfur species are formed under conditions of oxidative
stress11,12. Iron signals could be related to degradation of myo-
globin and other metalloproteins inside the lysosomes13. Com-
parative NanoSIMS analysis of myoglobinopathy samples with
one sample from a patient with Pompe disease containing
electron-dense inclusions, two samples showing abundant lipo-
fuscin and two muscle samples from patients affected with distal
myopathies with rimmed vacuoles, revealed that the amount of Fe
is higher in the myoglobinopathy sarcoplasmic bodies than in
other similar inclusions.
µFTIR analysis of muscle biopsy samples. Fourier transform
infrared microscopy (µFTIR) analysis of muscle samples
demonstrated increased carbonyl (ester) groups in the sarco-
plasmic bodies indicating lipid oxidation (Fig. 5k–m). Moreover,
some sarcoplasmic bodies showed a band at 1627 cm−1, which is
characteristic of intermolecular β-sheet structures14 (Fig. 5n) and
a feature typical of amyloid formation15,16. However, in vitro,
only small amounts of non-ﬁbrillar amyloid β-structure were
detected (see Supplementary Note 1 and Supplementary Fig. 6).
Non-ﬁbrillar β-sheet aggregates have been previously described
for other peptides and proteins including β-amyloid peptides
related to Alzheimer’s disease16. Both NanoSIMS and µFTIR,
therefore, suggest lipid oxidation in patients’ muscles contribute
to sarcoplasmic body formation.
Biochemical characterization. At the molecular level, the
His98Tyr variant might impact on different MB functional
Fig. 4 Immunohistochemical features of myoglobinopathy. a, b Small myoglobin aggregates are observed in some myoﬁber regions and in some
sarcoplasmic bodies (double arrow in b), but not in others (arrow in b). c p62 and ubiquitin d immunoreactivity is observed in some myoﬁber regions,
and in some, but not in all sarcoplasmic bodies indicating protein aggregates. Scale bars= 20 µm
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properties, crucial to the physiological role: these include the
interaction of MB with dioxygen, the afﬁnity of MB protein
scaffold to hemin, as well as the ability to keep the heme in the
reduced state (Fe2+). In vivo, ferrous MB (Fe2+), which is the
only myoglobin form that can bind and store O2, is prone to
autoxidation17, leading to functionally inactive MetMB (Fe3+),
which is eventually reduced back to ferrous MB by cytochrome
b518,19.
First, we evaluated whether the variant affects the afﬁnity of the
prosthetic group for the MB polypeptide matrix, as it has been
demonstrated that mutations in the vicinity of the porphyrin ring
can increase heme dissociation rates (k-H) by two-orders of
CH3
3000
0.6
* *
0.5
0.4
0.3
A
29
25
 c
m
–1
/A
16
54
 c
m
–1
A
17
40
 c
m
–1
/A
29
25
 c
m
–1
0.2
0.1
0.0 0.0
0.1
0.2
0.3
0.4
0.5
Sarcoplasmic
bodies
Surrounding muscle
tissue
Sarcoplasmic
bodies
Surrounding
muscle
tissue
2900 2800
Wavenumber (cm–1)
1700 1600 1500
1680 1660
α-helix + unordered
-sheet
0.005
d2
A
/d
(υ
)2
1640
Wavenumber (cm–1)
1620 1600
CH2 Amide
C=O
k
l m
n
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09111-2
6 NATURE COMMUNICATIONS |         (2019) 10:1396 | https://doi.org/10.1038/s41467-019-09111-2 | www.nature.com/naturecommunications
magnitude20–22. At pH 7.0, k-H of H98Y was ﬁve times higher
compared with WT (Table 2 and Supplementary Fig. 7).
Mutations of the corresponding residue (His97) in sperm whale
myoglobin into small and hydrophobic (e.g., Ala, Val) or acidic
(e.g., Glu, Asp) amino acids enhanced k-H21,22 owing to loss of
electrostatic interaction between the side chain of His97 and the
negatively charged heme propionate-721. His98 of human MB
contributes to modulating the solvent accessibility to the heme
pocket. Upon exchange of His98 with Tyr, the interaction with
the propionate is weakened; Tyr98 can still form H-bonds with
propionate-7, nevertheless, k-H is higher for p.His98Tyr com-
pared with WT MB. Notably, this change in k-H is in line with the
His97Phe mutant of sperm whale myoglobin21,22, reﬂecting
the similarity between Tyr and Phe in terms of steric hindrance.
Our interpretation is further supported by the fact that at pH
5.0 the k-H values for WT and p.His98Tyr are increased (1.44 ±
0.09 h−1 and 1.86 ± 0.05 h−1, respectively) and the difference
between the two species becomes smaller, because of protonation
of the heme propionates, resulting in diminished interaction of
the heme group with the protein.
Next, we investigated the impact of the mutation on the
oxidation state of the heme iron, both from a thermodynamic and
kinetic point of view. Oxidized and reduced MB coexist in
solution, and the ratio of the two forms is regulated thermo-
dynamically by the reduction potential E°’ and kinetically by the
protein autoxidation rate17, which in turn are inﬂuenced by pH,
oxygen concentration, and temperature23. The autoxidation
process is kinetically controlled under physiological conditions.
We observed nearly identical autoxidation rate constants kox for
WT and p.His98Tyr (see Table 2). Moreover, the spectral features
of deoxy-, oxy-, and metmyoglobin forms for both WT and
mutant are identical (Supplementary Fig. 8). On the contrary,
WT and p.His98Tyr feature slightly different reduction potential
(E°’) values. Spectroelectrochemical investigations yielded a E°’ of
(+0.040 ± 0.005) V vs SHE for WT MB, in excellent agreement
with previous ﬁndings24, whereas the reduction potential of the
p.His98Tyr myoglobin is shifted toward lower values (Fig. 6). E°’
determines the tendency of electron transfer from the Fe (II)
center to the bound dioxygen ligand25, a critical step of the
autoxidation process yielding inactive MetMB. From a purely
thermodynamic point of view, lower E°’ values would favor
formation of auto-oxidized MetMB.
Another important difference between WT and mutant MB
concerns the afﬁnity for molecular oxygen. Oxygen-binding
studies to both WT and mutant deoxymyoglobins showed
formation of oxymyglobin states (Soret band at 418 nm and
two distinct bands at 545 and 580 nm) (Fig. 7). Calculation of rate
constants, kon, of O2 binding from the slope of the linear plots
of kobs values versus O2 concentration (Fig. 7b) yielded apparent
bimolecular binding rates of (1.16 ± 0.7) × 107 M−1 s−1 (WT MB)
and (5.6 ± 0.2) × 106 M−1 s−1 (p.His98Tyr), respectively. From
the intercept, koff, of these plots, the dissociation constants, KD
(=koff/kon), were calculated to be (1.2 ± 1.1) µM and (8.4 ± 2.5) µM,
respectively (see Table 2), demonstrating a reduced afﬁnity of the
mutant MB for molecular oxygen.
To shed light onto the structural and dynamic changes
caused by the His-to-Tyr substitution underlying the complex
biochemical picture described above, we performed molecular
dynamics (MD) simulations of both WT and mutant species.
The analysis of our sampling suggests that the substitution does
not lead to major global structural rearrangements. The global
fold of the protein appears to be maintained (Fig. 6), and the
two proteins feature almost superimposable ﬂuctuation patterns
(Supplementary Note 2 and Supplementary Figs. 9 and 10).
Nevertheless, MD simulations indicated that the heme group
in p.His98Tyr is more solvent exposed than in the WT
protein. This may explain the shift of E°’, which is highly
(though not solely) inﬂuenced by the extent of exposure of
the heme to solvent26,27; the latter might also contribute
to the increment of KD for O2 binding to p.His98Tyr, owing
to the more polar environment resulting from enhanced
accessibility to water.
Initial studies using a reporter cell assay, suggest that mutant
myoglobin may result in elevated intracellular superoxide levels.
Fig. 5 Characterization of sarcoplasmic bodies, the morphological hallmark of myoglobinopathy. Electron micrographs a–d showing collections of highly
electron-dense bodies with some less dense material at their periphery. The sarcoplasmic bodies are seen under the sarcolemma (a) and often next to the
nuclei. Some sarcoplasmic bodies are surrounded by a membrane (b). Sarcoplasmic bodies of different electron densities near several vesicular structures
(c). Sarcoplasmic bodies observed in the cardiac muscle obtained post mortem from individuals F1, II:7 (d) and F3, III:5. Electron micrographs (e–g) and the
corresponding NanoSIMS images (h–j). Blue indicates sulfur (32S), red phosphorus (31P), and green (56Fe), respectively. Sarcoplasmic bodies interspersed
between the myoﬁbrils (e), next to nuclei (f), or inside an autophagic vacuole (g). Note the high-sulfur signal in the sarcoplasmic bodies (h–j), and the iron
signal (green dots within the sarcoplasmic bodies in i, j). Scale bar in a= 2 µm, b = 5 µm, c= 0.5 µm, d= 1 µm, h–j= 4 µm. k Typical µFTIR spectra and
their second derivative of the muscle tissue where the lipid region has been highlighted in orange and the protein region in blue; the inset shows the lipid/
protein ratio (calculated from the Infrared spectra) on an optical image of a tissue section with sarcoplasmic bodies. The color bar represents intensity of
the ratio: blue and red mean low and high lipid content, respectively. The scale bar is four microns. l Box plot graphic of lipid/protein ratio (2925 cm−1/
1654 cm−1). m Box plot graphics representing COOH/CH2 ratio indicating lipid oxidation (1739 cm−1/2925 cm−1). Ratios were calculated from the second
derivative of the spectra of three different samples from three different patients (at least 10 sarcoplasmic bodies per patient). Boxplots denote the median
(center line), interquartile range (box), whiskers that represents the most extreme data that are not >1.5x IQR from the edge of the box and outliers that
are the points outside this range. T-tests were used to compare the sarcoplasmic body ratios with the surrounding tissue ratios and determine the p value
(*p<0.005). n Infrared second derivative spectrum of the amide region of one sarcoplasmic body (green) showing an increase of β-sheet structures,
indicating protein aggregation. Second derivative of the amide region corresponding to the tissue surrounding the sarcoplasmic bodies (black)
Table 2 Effect of mutation on biochemical properties of MB
KD, O2 (µM) k-H at pH 7.0 (h−1) a k-H at pH 5.0 (h−1) b E°’ by spectroelectr. (V vs SHE) c E°’ by SWV (V vs SHE) c kOX at pH 7.0 (min−1) Heme SASA (nm2) d
WT 1.2 ± 1.1 0.22 ± 0.06 1.44 ± 0.09 +0.040 ± 0.005 −0.056 ± 0.015 1.96 ± 0.39 1.45 ± 0.04
His98Tyr 8.4 ± 2.5 1.19 ± 0.05 1.86 ± 0.05 +0.021 ± 0.005 −0.105 ± 0.015 1.97 ± 0.43 1.80 ± 0.05
Conditions: a0.2 M phosphate buffer, pH 7.0, and 0.45 sucrose (37 °C); b0.2 M acetate, pH 5.0, and 0.45 M sucrose (37 °C); c0.2 M phosphate buffer, pH 7.0 (25 °C). dValues obtained from MD
simulations
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HEK cells transfected with MBp.His98Tyr-EGFP had signiﬁcantly
elevated levels (1.45-fold, p= 0.007) of intracellular superoxide
compared with those transfected with wild-type MB-EGFP
(Fig. 7c). Further experimental investigations of structural and
functional changes caused by the substitution will shed more light
on the altered relationship between structure, dynamics, and
function in the p.His98Tyr variant.
Discussion
Myoglobin belongs to the globin superfamily. Mutations in
hemoglobin have been recognized for a long time and result in
hemoglobinopathies28. Two other globin proteins (cytoglobin and
neuroglobin) have not yet been associated with disease29. Our
ﬁndings allow us to describe the ﬁrst disorder caused by a
mutation in MB. We propose the disorder should be named
Myoglobinopathy. Family 3, ﬁrst described by Edstrom
et al.30,31in 1980, became a classic of the muscle disease literature
but its cause remained unsolved until now. Myoglobinopathy has
a recognizable clinical phenotype, characterized by disease onset
during the fourth or ﬁfth decade of life, manifesting with prox-
imal weakness in the lower extremities and axial muscles, pro-
gressing to involve proximal and distal muscles of all limbs with
later generalized weakness. Although initially described as a distal
myopathy30 our study demonstrates that all patients exhibit
proximal weakness as the initial symptom. Respiratory insufﬁ-
ciency is a frequent complication and is the cause of death in the
majority of patients. Indeed, most advanced patients will require
non-invasive respiratory support. Cardiomyopathy was demon-
strated in less than half of the patients. It is uncertain whether
myocardial involvement is an inconstant feature of the disease, or
it remains subclinical for a long time. In support of this last
hypothesis, post mortem examination of cardiac tissue in two
individuals who did not manifest symptoms of cardiac failure
showed large numbers of sarcoplasmic bodies.
The combination of proximal and axial weakness and
respiratory insufﬁciency share some similarities with the pheno-
type of patients suffering from late-onset Pompe disease. How-
ever, cardiomyopathy is usually not a feature of late onset Pompe
disease; moreover, distal muscle involvement as revealed by
clinical examination and muscle imaging studies does not occur
in late onset Pompe diseases until very late in the course of the
illness32.
The sarcoplasmic bodies are the pathological hallmark of the
disease and are the principal aid to diagnosis. They have some
similarities with lipofuscin33 and also with the globular dense
inclusions found in Pompe disease33,34 but they are much denser
and homogeneous, and usually lack the vacuolar lipid droplets
seen in these two conditions. They are also highly reminiscent of
the inclusions found in the skeletal muscles from patients with
chronic vitamin E deﬁciency, which are known to be the result of
lipid oxidation as a consequence of oxidative stress35.
MB accomplishes its physiological tasks thanks to an extremely
delicate balance of efﬁcient oxygen binding, resistance to auto-
xidation, and high heme afﬁnity. The full interplay between the
molecular properties affected by the pathogenic mutation is
obviously complex. However, it is apparent from our biochemical
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characterization that some key properties are altered upon
mutation, each with potential repercussions at the physiological
level. The increased k-H would make the mutant more prone to
heme loss, as previously seen with variant sperm whale
myoglobin21,22 and this could contribute to the formation of the
lipid and/or protein aggregates found in patients’ muscle owing
to the generation of ROS by free heme36. In support of this
hypothesis, we have shown experimentally, via a reporter cell
assay, that mutant myoglobin appears to be associated with ele-
vated levels of intracellular superoxide. As a consequence,
although myoglobin is expressed in oxidative myoﬁbers, the
impact of the mutation may be reﬂected in both myoﬁber types.
The E°’ shift may impact on myoglobin’s role as a regulator of
redox pathways in muscle, for example unbalancing the redox-
dependent mechanisms of oxygen-controlled NO formation37–39,
whereas the higher KD of the mutant MB for O2 might affect the
capability of MB to act as an oxygen storage species.
To date, all myoglobinopathy cases have been caused by the
same c.292C>T, (p.His98Tyr) missense variant in MB, thus
suggesting that this position may be a mutational hotspot. We
demonstrate that the c.292C>T, (p.His98Tyr) missense variant
is associated with altered oxygen binding and increased tendency
to heme loss. It remains to be seen whether other variants in
MB result in the same disease.
Methods
Patients. The 14 patients described in this study constitute a clinically and
pathologically homogeneous cohort of adult patients, belonging to six unrelated
families (F1–F6), (Fig. 1), originating from Spain (2), Sweden (1), France (2), and
The Netherlands (1). The families were principally identiﬁed by their highly
characteristic features on muscle biopsies. The clinical and pathological features of
the Swedish family have been described34,35 and the Dutch patient was brieﬂy
described in a workshop report40.
The study was approved by the ethics committees of the participating
institutions: IDIBELL-Hospital de Bellvitge, Karolinska Institutet, University of
Western Australia, Institut de Myologie, GHU Pitié-Salpêtrière, Hospices Civils de
Lyon, University Hospitals Leuven and Henri Mondor University Hospital Sample
collection was performed with written informed consent from the patients
according to the declaration of Helsinki.
Muscle biopsy. A muscle biopsy was performed for at least one affected patient per
family after written informed consent (Supplementary Table 1). In addition, post
mortem cardiac, skeletal, and diaphragm muscle samples were obtained from
individuals F1, II: 7 and post mortem cardiac and skeletal muscle was obtained
from individual F3: III: 5. Samples were processed for routine histochemical
analysis and for acid phosphatase activity, and Perls’ Prussian blue stain and
Alizarin Red for iron and calcium detection, respectively. Immunohistochemical
analysis was performed for myoglobin, ubiquitin, p62, and LAMP1. Cryostat sec-
tions, 8 μm thick, were incubated with 1% hydrogen peroxide in 1 × PBS (Phosphate
Buffer Saline) for 5 min in order to block endogenous peroxidase. Then, unspeciﬁc
binding reactions were blocked with 10% (goat) or 3% (horse) normal serum in 1 ×
PBS for 2h, followed by incubation of the corresponding primary antibody diluted
in 1 × PBS with 3% (goat) or 1% (horse) normal serum at 4 °C overnight. Mouse
monoclonal anti-myoglobin (Novus biologicals), anti-LAMP1 (Santa Cruz Bio-
technology, H-228:sc-5570), rabbit polyclonal anti-ubiquitin (Dako, z-458), and
guinea pig polyclonal antibody against the C-terminus of p62 (Progen, GP62-C)
were used at a dilution of 1:50, 1:100, 1:100, and 1:100, respectively. After washing,
the sections were processed with Super Sensitive Link-Label IHC Detection
System (BioGenex) following the instructions of the manufacturer. As sarcoplasmic
bodies are brown and diaminobenzidine (DAB) immunoreactions appear brown,
the immunoreactions were visualized as a dark blue precipitate using NH4NiSO4
diluted in phosphate buffer with 0.03% DAB, 0.04% NH4Cl, and 0.001%
hydrogen peroxide41. Sections were viewed with an Olympus BX43 microscope.
Non-stained sections were also examined with a Leica TCS-SL confocal microscope
under a wide range of visible laser excitation lines. A small sample of biopsy
tissue was ﬁxed in 2% glutaraldehyde, postﬁxed with 1% osmium tetroxide, and
embedded in araldite. Ultrathin sections were stained with uranyl acetate and lead
citrate, viewed with a JEOL 1011 electron microscope and photographs taken with a
gatan 782 camera.
Molecular genetics—the two Spanish families. Targeted capture and next
generation sequencing (ProtonTM, Life Technologies) of 336 genes including 254
neuromuscular disease genes listed in the Neuromuscular Disorders Gene Table at
the end of December 2012 (www.musclegenetable.fr) was performed in probands
from families F1 and F2. Exome enrichment was performed on DNA from the
proband (using an Ampliseq Whole Exome kit, Thermoﬁsher Scientiﬁc). In brief,
a total of 100 ng of DNA was ampliﬁed in 12 separate PCR pools, each containing
~ 25,000 primer pairs under the following conditions: 99 °C for 2 min followed by
10 cycles of 99 °C for 15 s and 60 °C for 16 min. After ampliﬁcation, the individual
reactions were pooled and digested using the supplied FuPa enzyme that degrades
the PCR primers. Next, barcoded sequencing adaptors were ligated and the library
was puriﬁed using AMPure beads (Beckman Coulter) and ampliﬁed for ﬁve cycles
using Platinum high-ﬁdelity polymerase. The ﬁnal ampliﬁed library was puriﬁed
again using AMPure beads and analyzed on a 2100 Bioanalyser (Agilent Tech-
nologies). Libraries were diluted to 18–26 pM. Attachment to Ion Sphere Particles
was done with the Ion Proton Template 200 V3 kit. Sequencing was performed on
P1 sequencing chips (520 ﬂows) using an Ion Proton sequencer and Ion Sequen-
cing 200 kit V3. After pooling, two samples were sequenced on one chip. After
sequencing, to remove low-quality bases from the 3’ end, reads were trimmed.
Reads were mapped to the genome reference sequence (Hg19) using tmap (Torrent
Suite 4.2). Torrent Variant caller was used to call variants with exome-optimized
custom settings. Ion Reporter 4.0 was used to annotate the data. Filtering of var-
iants was performed with ANNOVAR against three databases: ENCODE GENE-
CODE v.19, 1000genomes (threshold > 0.5%), dbSNP138 and also against a list of
common in-house variants42. The ﬁltered exome data were interrogated for var-
iants in a set of genes that were most highly enriched (>1000-fold) in skeletal
muscle samples within the FANTOM5 (functional annotation of the mammalian
genome) data set8. Using the FANTOM5 promoter level expression atlas, we
generated a ranked list of skeletal muscle enriched genes. Source ﬁle with pre-
computed relative expression was downloaded from http://fantom.gsc.riken.jp/5/
tet/data/hg19.cage_peak_phase1and2combined_rel_expr.txt.gz. We identiﬁed the
promoter for every gene with the most enriched expression in 76 skeletal muscle
samples and compared this with the median expression across the entire FAN-
TOM5 collection [log10(max expression in any skeletal muscle sample+ 1)—log10
(median expression in the FANTOM5 collection+ 1)]. A promoter for 82 anno-
tated protein-coding genes was identiﬁed showing > 1000-fold enriched expression
in skeletal muscle. Thirty-one of these genes had previously been associated with a
genetic muscle disease in humans. The 51 genes that had not previously been
associated with human muscle disease we prioritized as candidate myopathy genes.
Genome-wide linkage analysis of the Swedish family—Family 3. Genome-wide
linkage analysis was performed using genotypes of 550 microsatellite markers.
Genotype errors were checked and removed prior to analyses by using PedCheck43
GENEHUNTER v. 2.144 as used for both parametric and non-parametric linkage
analysis. Parametric linkage analysis was performed assuming an autosomal
dominant model with a penetrance of 0.999 for heterozygotes, disease-allele fre-
quency of 0.001, and phenocopy rate of 0.001. LOD scores were calculated under
the same dominant model. Both multipoint and single-point analyses were per-
formed. The positions of marker loci were based on published human genetic maps
(National Center for Biotechnology Information).
Target sequencing in the Swedish Family. Targeted capture and sequencing
included > 400 genes surrounding the peak multipoint LOD score. Enrichment for
the target-sequencing region was obtained by using a custom-designed NimbleGen
SeqCap EZ Developer library (Roche NimbleGen, Inc. Madison, WI 53719 USA).
Eight samples, two healthy controls, and six patients, from the Swedish family, F3,
were selected for targeted sequencing. The sequencing was done at SciLifeLab
Stockholm, Sweden. All samples yielded the expected number of sequencing reads.
Each DNA library was prepared from 3 μg of the pooled genomic DNA. DNA was
sheared to 300 bp using a Covaris S2 instrument and enriched by using the custom-
designed NimbleGen SeqCap kit. The clustering was performed on a cBot cluster
generation system using a HiSeq paired-end read cluster generation kit according
to the manufacturer’s instructions. The samples were sequenced on an Illumina
HiSeq 2000 as paired-end reads to 100 bp. The sequencing runs were performed
according to the manufacturer’s instructions. Base conversion was done using
Illumina’s OLB v1.9.
Sanger sequencing. The MB c.292C>T (p.His98Tyr) variant was identiﬁed in
Families F1 to F3 through NGS. The presence of the variant in these three families
was Sanger conﬁrmed. Families F4, F5 and F6 were screened for mutations in MB
using Sanger sequencing. Segregation studies were performed in all families
including samples from all available affected and unaffected relatives using Sanger
sequencing. MB primers are included in Supplementary Methods 1.
In silico predictions. The in silico pathogenicity predictors used were: Mutatio-
nAssessor45, MutationTaster46, PolyPhen-247, Provean48, and SIFT49.
Haplotype analysis. To test for possible founder effects, we studied eight infor-
mative microsatellite markers (D22S685, D22S691, D22S1152, D22S1265, (MB),
D22S277, D22S683, D22S692, IL2RB) spanning 3 Mb around MB using multiplex
polymerase chain reaction with labeled primers and fragment analysis. Gene-
Mapper software was used for the fragment analysis. The primers used in haplo-
type analysis are included in the Supplementary Methods 2.
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Correlative electron microscopy and NanoSIMS imaging. For NanoSIMS
(Nanoscale Secondary Ion Mass Spectrometry) imaging, 500 nm sections of resin
embedded muscle samples from individuals F1 II: 5, and II: 7 and F2 II:2 were
mounted on platinum coated coverslips, and then transferred into a FEI Verios
scanning electron microscope (SEM) for backscattered electron (BSE) imaging50. A
1–2 kV electron beam with current of ~ 100pA was used for BSE imaging. Sections
were then coated with 5 nm platinum by a SC 7640 Polaron sputter coater, and
transferred into the NanoSIMS 50L (CAMECA, France) for chemical analysis. The
same areas imaged by SEM were analyzed by the NanoSIMS for chemical dis-
tribution. A 16 keV Cs+ primary beam is used to detect 31P–, 32S–, and 56Fe16O.
For comparative purposes, in addition to myoglobinopathy samples, we
performed NanoSIMS analysis in one sample from a patient with Pompe disease
containing electron-dense inclusions, two samples showing abundant lipofuscin
and two muscle samples from patients affected with distal myopathies with
rimmed vacuoles.
Fourier transform infrared microscopy. 10 μm-thick cryostat muscle sections
were obtained from individuals F1, II: 5 and II: 7, F2, II:2, F3, III:5, II:15 and
IV:6 and deposited on CaF2 windows and allowed to dry. Samples were kept at
vacuum conditions before the infrared spectroscopy analysis. μFTIR experiments
were performed at the MIRAS beamline in the ALBA synchrotron, Spain using
a Hyperion 3000 Microscope coupled to a Vertex 80 spectrometer (Brucker)
equipped with 36x magniﬁcation objective. The measuring range was 900
−4000 cm−1 and the spectra collection was done in transmission mode at 4 cm−1
spectral resolution, 10 μm× 10 μm aperture dimensions using an mercury cad-
mium telluride (MCT) detector. For each spectrum 128 scans were co-added.
Background spectra were collected from a clean area of each CaF2 window. FTIR
data were analyzed using OPUS 7.5 (Brucker) and Origin 9.1. The spectra exhi-
biting strong Mie scattering were eliminated and second derivation of the spectra
was applied in order to eliminate the baseline and improve the resolution of the
different bands using a Savitzky−Golay algorithm with a 15-point ﬁlter and a
polynomial order of two. The assignments of Infrared bands are well-established
for proteins and lipids and are shown in Fig. 5c. The derivative of each FTIR
spectrum was computed and the ratios for lipid oxidation (1741 cm−1/2925 cm−1,
CO/−CH2) and lipid protein ratio (2925 cm−1/1654 cm−1 Amide I/−CH2)
calculated51.
Expression and puriﬁcation of recombinant WT and mutant MB. pET-19b
plasmids with human WT, p.His98Tyr or p.His65Tyr/Val69Phe myoglobin
cDNA (the latter to be used for heme loss kinetic studies, see below) cloned into
them were purchased (GenScript USA Inc.) and then transformed in Escherichia
Coli BL21(DE3) for the production of N-terminally His-tagged fusion myoglo-
bins. Luria-Bertani medium supplemented with ampicillin (100 μg/ml) was
inoculated with a freshly prepared overnight culture (at a dilution ratio of 1:100).
The culture was grown at 37 °C under agitation (220 rpm) until OD600= 0.6 was
reached. The temperature and the shaker speed were reduced to 20 °C and 100
rpm and hemin was added to a ﬁnal concentration of 15 μg/mL. After 30 min,
isopropyl-β-d-thiogalactopyranoside was added to a ﬁnal concentration of 0.5
mM. Please note that p.His65Tyr/Val69Phe for the hemin loss rate experiments
was grown using the same procedure but no hemin was added. To make sure
that the double mutant was in the apo form, 3.5 mg of protein at pH 2.5 were
extracted using an equal volume of 2-butanone, shaking three times for 5 min
and then incubating the mixture for 10 min at 4 °C20. The aqueous phase was
dialyzed at 4 °C against 1 l of water and then against 1 l of 0.2 M phosphate buffer
pH 7 or 0.2 M acetate buffer pH 5. After 12 h, the culture was centrifuged,
resuspended in 50 mM phosphate buffer, 150 mM NaCl, and 20 mM imidazole
(pH 7.5), lysed by sonication and clariﬁed by centrifugation. The proteins were
puriﬁed by afﬁnity chromatography (HisTrap FF crude columns (GE Health-
care) connected to an AKTA Prime chromatographic system (Amersham
Pharmacia Biotech) and subsequently by gel ﬁltration chromatography (HiLoad
16/60 Superdex 75 prep grade (Amersham Biosciences). The purity of the
fractions was checked by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis and UV-Vis spectroscopy.
WT and His98Tyr variant myoglobin aggregation test. WT MB and the variant
His98Tyr MB were incubated in 10mM phosphate buffer at pH 7.4 at 37 °C and 200
rpm agitated for 1 week. At different times, aliquots were taken for ThT Fluores-
cence and Infrared Spectroscopy measurements. For ﬁbril ﬂuorescence detection,
Thioﬂavin T (ThT) (SIGMA-Aldrich), a ﬂuorescence dye speciﬁc to ﬁbrils, was
added to the solution. In total, 8 mM ThT stock solutions were prepared in 10mM
phosphate buffer at pH 7.4 buffer and ﬁltered through a 0.45 μm syringe driven
ﬁlter unit (Millipore). ThT ﬁnal concentration in the ﬂuorescence cuvette was 35 μM.
Excitation and emission wavelengths were set at 450 and 490 nm, respectively, using
a PTI ﬂuorimeter. Temperature was 37 °C. For Infrared spectra, 3 μL of the different
samples were deposited on CaF2 windows and dried under vacuum. Infrared spectra
were measured at MIRAS beamline in ALBA synchrotron.
Electrochemical measurements. All spectroelectrochemical experiments were
conducted in a homemade OTTLE (optical transparent thin-layer spectro-
electrochemical) cell, in a three-electrode conﬁguration that consisted of a gold
minigrid working electrode (Buckbee-Mears, Chicago, IL), an Ag/AgCl/3M KCl
microreference electrode (373/SSG/6, Amel electrochemistry, Milano, Italy) and a
platinum wire as the counter electrode. Potentials were applied across the OTTLE
cell with an Amel model 2053 potentiostat/galvanostat. A constant temperature
was maintained by a circulating water bath, and the OTTLE cell temperature was
monitored with a micro thermo-couple. UV−vis spectra were recorded using a
Varian Cary C50 spectrophotometer. The OTTLE cell was ﬂushed with argon gas
to establish an oxygen-free environment in the cell. Experiments were conducted at
a constant temperature of 25 °C, using 600 μL samples containing 15 μM of protein
in 50 mM phosphate buffer (pH 7.0) 20 mM NaCl and 30 μM phenazine metho-
sulfate. Nernst plots consisted of at least ﬁve points and were invariably linear with
a slope consistent with a one-electron reduction process. Square wave voltam-
mograms were recorded using a Potentiostat/Galvanostat mod. 273A (EG&G PAR,
Oak Ridge, USA). A graphite disk electrode, a Pt wire and a saturated calomel
electrode (SCE) were used as working, counter and reference electrode, respec-
tively. The electric contact between the SCE and the working solution was achieved
with a Vycor® (PAR) set. The working electrode was cleaned before each use with
mechanical polishing with 0.5 μm aluminum oxide followed by 5 min in an
ultrasound bath. Myoglobin was deposited on the electrode by drop casting 10 μL
of a solution containing 100 μM protein and 20 mM phosphate buffer (pH 7.0). The
electrode was then incubated overnight at 4 °C. The following step was to drop cast
20 μL of a solution containing 10% m/m of gelatin type A (Sigma-Aldrich, G1890)
and 20 mM phosphate buffer (pH 7.0), followed by incubation at room temperature
for 2 hours. The electrode was then ready for electrochemical measurements. The
working solution was 20 mM phosphate buffer (pH 7.0). Experiments were carried
out under argon atmosphere at 25 °C. The errors associated to the E°’ values are the
standard deviations calculated over at least three independent sets of measurements
for each species.
Measurement of hemin loss rates for WT and p.His98Tyr. Hemin
dissociation kinetics was investigated as follows: we monitored the decrease with
time (0–350 min) of the absorbance at 410 nm for the transfer of the heme from
holo WT (or p. His98Tyr) MB to the apo MB double mutant p.His65Tyr/
Val69Phe20,21 in a 1:10 concentration ratio. Time courses were ﬁtted to a single-
exponential expression in GraphPad Prism 5.0 (GraphPad Software, Inc., San
Diego, CA) to obtain the ﬁrst order dissociation rate constant for hemin loss k-H.
The experiments were conducted at 37 °C in the presence of 0.45 M sucrose, in 0.2 M
phosphate buffer at pH 7 or 0.2 M acetate buffer pH 5. UV−vis spectra were
recorded using a Varian Cary C50 spectrophotometer.
Molecular modeling. For each protein, three 350 ns-long MD simulations were
produced using the 5.0.4 version of the GROMACS software. The starting
structure of human myoglobin was taken from the PDB ﬁle 3RGK52. The pro-
gram Modeller53–56 was used to edit the 3RKG.pdb ﬁle. The structure of the C-
terminus was taken from the PDB ﬁle 1MWD57. The structure of the p.His98Tyr
mutant was obtained by homology modeling using Modeller and taking the
3RGK ﬁle as template structure. All the simulations were performed in the
reduced ensemble. The starting structures were ﬁrst relaxed in vacuum using the
steepest descent algorithm, 3000 steps, and then put in a rhombic dodecahedral
box, ﬁlled with TIP3P water molecules. Na+ and Cl− were added to neutralize
the protein total charge and to have a ﬁnal concentration of 100 mM. The sys-
tems were then relaxed with the conjugate gradients algorithm in two steps.
Then the systems were annealed to 300 K, starting from 50 K, in a 100 ps run.
The systems were then equilibrated in three successive runs, each 500 ps long: (i)
an NVT at 300 K58, (ii) an NPT at 300 K, 1 bar (iii) an NPT at 300 K and 1 bar59.
The last frame was used as a starting structure for the MD production run in the
NPT ensemble, at a temperature of 300 K and a pressure of 1 bar. All bond
lengths were constrained using the LINCS algorithm60 and an integration step of
2.0 fs was used. Long-range electrostatics was computed by the Particle Mesh
Ewald method61, with a grid spacing of 0.12 nm combined with a fourth-order
cubic interpolation and a real space cutoff of 0.9 nm. During all the runs, the
CHARMM27 force ﬁeld62 with CMAP correction63 was used. The three repli-
cates for each system were made using the same starting structure, but changing
the seed for the velocities random generator. The determination of the Solvent
Accessible Surface Area (SASA), the analysis of the distances, the analysis of
secondary structure, the Essential Dynamics (ED), the root mean square ﬂuc-
tuations calculations and the clustering analysis, were performed using the
corresponding Gromacs packages. The ED analyses were performed using the
backbone atoms of residues 1–150 both for the ﬁtting and the calculation of the
covariance matrix. The clustering procedure was made with a cutoff of 0.11 nm
and the Gromos method64. The centroids of the ﬁrst clusters were used for the
structure comparison. ED analysis was used to investigate the conformational
space spanned by WT and mutant p.His98Tyr myoglobin within the molecular
dynamics (MD) simulation and visualize the principal motions associated with
each species. To assess the differences between the ﬂuctuation patterns char-
acteristic of WT myoglobin and the p.His98Tyr mutant, the equilibrated tra-
jectories were linked for the two species into a single molecular dynamics
ensemble (concatenated trajectory) and essential dynamics analysis was per-
formed. The concatenated trajectory was projected onto a plane deﬁned by the
ﬁrst two eigenvectors of motions, which are usually referred to as the essential
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plane. This allowed a two-dimensional representation of the conformational
landscape explored during the MD simulations, and for the calculation of the
corresponding Free Energy Landscape.
Oxygen binding to wild-type human myoglobin and the variant His98Tyr.
Time-resolved binding of oxygen (O2) to wild-type human myoglobin and the
variant His98Tyr was monitored by stopped-ﬂow spectroscopy in the conventional
mixing mode. The stopped-ﬂow apparatus (model SX 18MV, Applied Photo-
physics) was equipped with a diode-array detector and an optical quartz cell with a
path length of 10 mm (volume: 20 µL). The fastest time of mixing was 0.68 ms. All
measurements were performed at 25 °C. In order to establish O2-free starting
conditions, all solutions were degassed with Argon. The stopped-ﬂow apparatus
(all syringes and tubings) was extensively ﬂushed with O2-free buffer (20 mM
phosphate buffer, pH 7.0; 20 mM NaCl). The concentration of wild-type MB and of
the variant in the cell was 1 µM. Prior to measurements, the degassed O2-free
protein solutions were reduced with sodium dithionite (ﬁnal concentration 25 µg
mL−1). To test oxygen binding, O2-free buffer was ﬂushed with O2 for different
time spans and the O2 concentration was determined using a thermostatted (25 °C)
Clark-type electrode (Oxygraph Plus; Hansatech Instruments, Norfolk, United
Kingdom). The electrode was equilibrated to 100% O2 saturation by bubbling O2
through the buffer and for 0% saturation by bubbling with N2 until the respective
plateaus were reached to derive an offset and a calibration factor. Experiments were
conducted in 20 mM phosphate buffer, pH 7.0, supplemented with 20 mM NaCl.
Dioxygen binding was determined by monitoring the absorbance increase at 418
nm. The apparent second-order rate constants, kon, were obtained from the slope of
a plot of kobs values (derived from single-exponential ﬁt of the respective time
traces at 418 nm) versus the dioxygen concentration; koff was derived from the
intercept of this plot.
Assessment of cellular superoxide. HEK293FT cells (p15-20) (Invitrogen)
were seeded onto coverglass pre-coated with Matrigel (Corning) in 12-well
tissue culture plates. Cells were transfected with pcDNA3.1 expression plasmids
containing full length human wild-type (MBWT) or c.292C>T MB (MBp.His98Tyr)
cDNA fused with an EGFP tag (Genscript). Transfections were performed using
1 μg of DNA and Lipofectamine® 3000 (Thermoﬁsher) as per manufacturer’s
instructions. Experiments were performed 48–72 h post transfection and were
conducted over three independent experiments. Plasmids are available upon
request. Basal superoxide generation was assessed65 in individual cells expressing
MBWT and MBp.His98Tyr (as indicated by EGFP positivity) using the
ﬂuorescent indicator dihydroethidium (DHE, 5 μM, 515–560 nm ex ﬁlter, 590
long pass em) at 37 °C. Fluorescent DHE signal was measured on a Hamamatsu
Orca ER digital camera attached to an inverted Nikon TE2000-U microscope.
Fluorescent images were taken at 1 min intervals with 200 ms exposure. Meta-
morph 6.3 was used to quantify the signal by manually tracing individual cells.
An equivalent region not containing cells was used as background and was
subtracted. DHE ﬂuorescence for each cell was recorded as the slope of the
signal measured over the course of 20 min, normalized to ﬂuorescent signal
recorded at 1 min.
Data availability
The source data underlying Figs. 5, 6, and 7 are provided in the Source Data ﬁle. The novel
variant here reported has been deposited in ClinVar, accession number: SCV000882438.
Patients’ consents were not obtained for public deposition of sequencing data, but these are
available upon reasonable request. Any additional data that support the ﬁndings of this
study are available from the corresponding author upon reasonable request.
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